


## GLOBAL NEWS

### VETERINARIANS SEE BENEFIT TO CANINE OA MANAGEMENT PROTOCOLS<sup>1</sup>




The American Animal Hospital Association (AAHA) conducted a survey, in collaboration with Denis Marcellin-Little from UC Davis and American Regent Animal Health, revealing a strong consensus among veterinarians on the need for a structured protocol to manage canine osteoarthritis (OA), particularly emphasizing early detection in younger dogs. Out of nearly 800 veterinarians surveyed, about 95% agreed on the necessity for such protocols. The importance of early detection is highlighted by a study showing radiographically visible OA is common in young dogs, with many cases undiagnosed and undertreated.

Veterinarians reported using a range of treatments for OA management, including weight management, joint supplements, exercise, drugs like PSGAG, NSAIDs, and pain control medications.

The survey also indicated a need for better education and standardized protocols for OA management, with a focus on early disease management, disease prevention, and client education. Despite the recognition of the need for structured protocols, there is variability in when veterinarians choose to implement these protocols, with only a small percentage applying them at the first visit for all dogs or at-risk dogs.

In conclusion, the survey calls for an increased focus on early detection and standardized management of canine OA, alongside improved education for both veterinarians and clients, to better address this prevalent condition.

### URINALYSIS OFFERS A NONINVASIVE, RAPID SCREENING FOR CANINE CANCER DETECTION



Cancer is the leading cause of death in adult dogs<sup>1</sup> with 50% of canines over age 10 dying from this disease.<sup>2</sup> Because of its prevalence, veterinary researchers can continuously working to find better options for diagnostic and early detection techniques.

Researchers have developed two innovative cancer detection methods for dogs. PetDx offers a liquid biopsy test analysing cell-free DNA from blood for cancer diagnosis. Meanwhile, a study by Virginia Tech researchers introduces a non-invasive urine test using Raman spectroscopy, capable of distinguishing cancerous conditions with over 90% accuracy. This urine test, detailed in *Frontiers in Veterinary Science*, offers a rapid and potentially home-based alternative to traditional blood tests, which are less accurate and more resource-intensive. These advancements not only aim to detect cancer earlier but also to monitor treatment responses and evaluate tumour characteristics, with potential future applications in both veterinary and human medicine. The survey also indicated a need for better education and standardized protocols for OA management, with a focus on early disease management, disease prevention, and client education. Despite the recognition of the need for structured protocols, there is variability in when veterinarians choose to implement these protocols, with only a small percentage applying them at the first visit for all dogs or at-risk dogs.

In conclusion, the survey calls for an increased focus on early detection and standardized management of canine OA, alongside improved education for both veterinarians and clients, to better address this prevalent condition.

Vivaldis, in association with the PLRC's Paws Learning & Research Council, an India associate member of FASAVA, organised the 4th Indian VET Expo 2024 and Pet Industry Forum Summit in New Delhi from January 21st to 23rd, 2024.



## VIVALDIS CORNER



### CANINE LONGEVITY DRUG STARTS CLINICAL TRIAL<sup>3</sup>




Boo, a Whippet, Receives First Dose in Study Targeting Lifespan Extension in Dogs with LOY-002 Treatment.

Loyal, a biotech company, has initiated the STAY study with the first dose of LOY-002 given to an 11-year-old whippet named Boo, aiming to extend the healthy lifespan of senior dogs. This pivotal trial, conducted in partnership

with over 50 veterinary clinics nationwide, seeks to gather data for FDA approval. The study, which will run parallel to an FDA conditional approval application, targets a 2025 availability for LOY-002 and will last four years. Loyal's CEO, Celine Halioua, emphasized the significance of the collaboration with veterinarians, technicians, and dog owners in this extensive effort. The study also includes the creation of a longitudinal biobank from participants to support longevity research in dogs and potentially humans. LOY-002, a daily beef-flavored pill for dogs aged 10 and older, aims to enhance metabolic health and mitigate age-related diseases. This follows Loyal's announcement of LOY-001 for large-breed dogs, expanding their focus to include small senior breeds. Boo, an 11-year-old whippet, is the recipient of the first dose of life-extending drug LOY-002. Photo courtesy John Poisson.

## VETERINARIANS SEE BENEFIT TO CANINE OA MANAGEMENT PROTOCOLS



The American Animal Hospital Association (AAHA) conducted a survey, in collaboration with Denis Marcellin-Little from UC Davis and American Regent Animal Health, revealing a strong consensus among veterinarians on the need for a structured protocol to manage canine osteoarthritis (OA),

particularly emphasizing early detection in younger dogs. Out of nearly 800 veterinarians surveyed, about 95% agreed on the necessity for such protocols. The importance of early detection is highlighted by a study showing radiographically visible OA is common in young dogs, with many cases undiagnosed and undertreated.

Veterinarians reported using a range of treatments for OA management, including weight management, joint supplements, exercise, drugs like PSGAG, NSAIDs, and pain control medications.


The survey also indicated a need for better education and standardized protocols for OA management, with a focus on early disease management, disease prevention, and client education. Despite the recognition of the need for structured protocols, there is variability in when veterinarians choose to implement these protocols, with only a small percentage applying them at the first visit for all dogs or at-risk dogs.

In conclusion, the survey calls for an increased focus on early detection and standardized management of canine OA, alongside improved education for both veterinarians and clients, to better address this prevalent condition.

## URINALYSIS OFFERS A NONINVASIVE, RAPID SCREENING FOR CANINE CANCER DETECTION

Cancer is the leading cause of death in adult dogs<sup>1</sup> with 50% of canines over age 10 dying from this disease.<sup>2</sup> Because of its prevalence, veterinary researchers can continuously working to find better options for diagnostic and early detection techniques.

Researchers have developed two innovative cancer detection methods for dogs. PetDx offers a liquid biopsy test analysing cell-free DNA from blood for cancer diagnosis. Meanwhile, a study by Virginia Tech researchers introduces a non-invasive urine test



using Raman spectroscopy, capable of distinguishing cancerous conditions with over 90% accuracy. This urine test, detailed in Frontiers in Veterinary Science, offers a rapid and potentially home-based alternative to traditional blood tests, which are less accurate and more resource-intensive. These advancements not only aim to detect cancer earlier but also to monitor treatment responses and evaluate tumour characteristics, with potential future applications in both veterinary and human medicine. The survey also indicated a need for better education and standardized protocols for OA management, with a focus on early disease management, disease prevention, and client education.


In conclusion, the survey calls for an increased focus on early detection and standardized management of canine OA, alongside improved education for both veterinarians and clients, to better address this prevalent condition.

## VIVALDIS CORNER

Vivaldis, in association with the PLRC's Paws Learning & Research Council, an India associate member of FASAVA, organised the 4th Indian VET Expo 2024 and Pet Industry Forum Summit in New Delhi from January 21st to 23rd, 2024.



## CANINE LONGEVITY DRUG STARTS CLINICAL TRIAL<sup>3</sup>



Boo, a Whippet, Receives First Dose in Study Targeting Lifespan Extension in Dogs with LOY-002 Treatment.

Loyal, a biotech company, has initiated the STAY study with the first dose of LOY-002 given to an 11-year-old whippet named Boo, aiming to extend the healthy lifespan of senior dogs. This pivotal trial, conducted in partnership with over 50 veterinary clinics nationwide,

seeks to gather data for FDA approval. The study, which will run parallel to an FDA conditional approval application, targets a 2025 availability for LOY-002 and will last four years. Loyal's CEO, Celine Halioua, emphasized the significance of the collaboration with veterinarians, technicians, and dog owners in this extensive effort. The study also includes the creation of a longitudinal biobank from participants to support longevity research in dogs and potentially humans. LOY-002, a daily beef-flavored pill for dogs aged 10 and older, aims to enhance metabolic health and mitigate age-related diseases. This follows Loyal's announcement of LOY-001 for large-breed dogs, expanding their focus to include small senior breeds. Boo, an 11-year-old whippet, is the recipient of the first dose of life-extending drug LOY-002. Photo courtesy John Poisson.